AU2004287561B2 - Bengamide derivatives, method for the production thereof and use thereof for the treatment of cancer - Google Patents
Bengamide derivatives, method for the production thereof and use thereof for the treatment of cancer Download PDFInfo
- Publication number
- AU2004287561B2 AU2004287561B2 AU2004287561A AU2004287561A AU2004287561B2 AU 2004287561 B2 AU2004287561 B2 AU 2004287561B2 AU 2004287561 A AU2004287561 A AU 2004287561A AU 2004287561 A AU2004287561 A AU 2004287561A AU 2004287561 B2 AU2004287561 B2 AU 2004287561B2
- Authority
- AU
- Australia
- Prior art keywords
- compound
- formula
- salt
- bengamide
- medicament
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 206010028980 Neoplasm Diseases 0.000 title claims description 22
- 201000011510 cancer Diseases 0.000 title claims description 16
- 238000000034 method Methods 0.000 title claims description 16
- 238000004519 manufacturing process Methods 0.000 title claims description 15
- 238000011282 treatment Methods 0.000 title claims description 5
- 229930195545 bengamide Natural products 0.000 title description 41
- GPVKLYONJSSZFL-UHFFFAOYSA-N NSC 750259 Natural products CCC(C)C=CC(O)C(O)C(O)C(OC)C(=O)NC1CCCCNC1=O GPVKLYONJSSZFL-UHFFFAOYSA-N 0.000 title description 29
- 150000001875 compounds Chemical class 0.000 claims description 74
- 150000003839 salts Chemical class 0.000 claims description 23
- 241001647006 Myxococcus virescens Species 0.000 claims description 22
- 239000000203 mixture Substances 0.000 claims description 20
- 244000005700 microbiome Species 0.000 claims description 14
- 239000001963 growth medium Substances 0.000 claims description 12
- 239000002609 medium Substances 0.000 claims description 10
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 9
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 8
- 230000008569 process Effects 0.000 claims description 8
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 5
- LCWXJXMHJVIJFK-UHFFFAOYSA-N Hydroxylysine Natural products NCC(O)CC(N)CC(O)=O LCWXJXMHJVIJFK-UHFFFAOYSA-N 0.000 claims description 5
- YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 claims description 5
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 claims description 5
- QJHBJHUKURJDLG-UHFFFAOYSA-N hydroxy-L-lysine Natural products NCCCCC(NO)C(O)=O QJHBJHUKURJDLG-UHFFFAOYSA-N 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 238000011321 prophylaxis Methods 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 27
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 27
- 210000004027 cell Anatomy 0.000 description 22
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 21
- 239000000126 substance Substances 0.000 description 21
- 239000000243 solution Substances 0.000 description 16
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 description 14
- 235000015097 nutrients Nutrition 0.000 description 13
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 12
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 238000004587 chromatography analysis Methods 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 229920001817 Agar Polymers 0.000 description 8
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 8
- 239000008272 agar Substances 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- QBOZJYBWSKZELU-UHFFFAOYSA-N bengamide E Natural products CC(C)C=CC(O)C(O)C(O)C(OC)C(=O)NC1CCCCNC1=O QBOZJYBWSKZELU-UHFFFAOYSA-N 0.000 description 7
- QBOZJYBWSKZELU-XMBAGFDESA-N bengamide E Chemical compound CC(C)/C=C/[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC)C(=O)N[C@H]1CCCCNC1=O QBOZJYBWSKZELU-XMBAGFDESA-N 0.000 description 7
- 230000004663 cell proliferation Effects 0.000 description 7
- 229960002104 cyanocobalamin Drugs 0.000 description 7
- 235000000639 cyanocobalamin Nutrition 0.000 description 7
- 239000011666 cyanocobalamin Substances 0.000 description 7
- 239000003960 organic solvent Substances 0.000 description 7
- 239000012071 phase Substances 0.000 description 7
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 6
- 239000005695 Ammonium acetate Substances 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- 235000019257 ammonium acetate Nutrition 0.000 description 6
- 229940043376 ammonium acetate Drugs 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 210000004881 tumor cell Anatomy 0.000 description 6
- 239000012138 yeast extract Substances 0.000 description 6
- PKRBZXVKAMNZBZ-WWIZSIRBSA-N (e,2r,3r,4s,5r)-3,4,5-trihydroxy-n-[(3s,6s)-6-hydroxy-1-methyl-2-oxoazepan-3-yl]-2-methoxy-8-methylnon-6-enamide Chemical compound CC(C)/C=C/[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC)C(=O)N[C@H]1CC[C@H](O)CN(C)C1=O PKRBZXVKAMNZBZ-WWIZSIRBSA-N 0.000 description 5
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 5
- BICMAOCAFVQWDC-UHFFFAOYSA-N Bengamide F Natural products CC(C)C=CC(O)C(O)C(O)C(OC)C(=O)NC1CCCCN(C)C1=O BICMAOCAFVQWDC-UHFFFAOYSA-N 0.000 description 5
- 239000007995 HEPES buffer Substances 0.000 description 5
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 5
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 108010079058 casein hydrolysate Proteins 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000000855 fermentation Methods 0.000 description 5
- 230000004151 fermentation Effects 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 229940041514 candida albicans extract Drugs 0.000 description 4
- 239000000824 cytostatic agent Substances 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 4
- 235000019341 magnesium sulphate Nutrition 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 241000461790 Astrophorina Species 0.000 description 2
- 239000002028 Biomass Substances 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- PLUBXMRUUVWRLT-UHFFFAOYSA-N Ethyl methanesulfonate Chemical compound CCOS(C)(=O)=O PLUBXMRUUVWRLT-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical class Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 241000116118 Jaspis Species 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 2
- VZUNGTLZRAYYDE-UHFFFAOYSA-N N-methyl-N'-nitro-N-nitrosoguanidine Chemical compound O=NN(C)C(=N)N[N+]([O-])=O VZUNGTLZRAYYDE-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical class OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 229910017052 cobalt Inorganic materials 0.000 description 2
- 239000010941 cobalt Substances 0.000 description 2
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- JBKVHLHDHHXQEQ-UHFFFAOYSA-N epsilon-caprolactam Chemical group O=C1CCCCCN1 JBKVHLHDHHXQEQ-UHFFFAOYSA-N 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 238000005227 gel permeation chromatography Methods 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 229910052748 manganese Inorganic materials 0.000 description 2
- 239000011572 manganese Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 239000000401 methanolic extract Substances 0.000 description 2
- 239000005445 natural material Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 150000005846 sugar alcohols Chemical class 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- -1 vincristine Chemical compound 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- SWFHGTMLYIBPPA-UHFFFAOYSA-N (4-methoxyphenyl)-phenylmethanone Chemical compound C1=CC(OC)=CC=C1C(=O)C1=CC=CC=C1 SWFHGTMLYIBPPA-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- 241001300211 Ancorinidae Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241001547834 Calthropella Species 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 230000004668 G2/M phase Effects 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010068370 Glutens Proteins 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 240000002024 Gossypium herbaceum Species 0.000 description 1
- 235000004341 Gossypium herbaceum Nutrition 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 241000244206 Nematoda Species 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 241000243142 Porifera Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- PFRKTXMXGDERHT-UCDUEDMDSA-N [(3s,6s)-1-methyl-7-oxo-6-[[(e,2r,3r,4s,5r)-3,4,5-trihydroxy-2-methoxy-8-methylnon-6-enoyl]amino]azepan-3-yl] tetradecanoate Chemical class CCCCCCCCCCCCCC(=O)O[C@H]1CC[C@H](NC(=O)[C@H](OC)[C@H](O)[C@@H](O)[C@H](O)\C=C\C(C)C)C(=O)N(C)C1 PFRKTXMXGDERHT-UCDUEDMDSA-N 0.000 description 1
- 150000001241 acetals Chemical class 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 230000002152 alkylating effect Effects 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000012482 calibration solution Substances 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 238000012054 celltiter-glo Methods 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229920001429 chelating resin Polymers 0.000 description 1
- 239000002962 chemical mutagen Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 238000011210 chromatographic step Methods 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000009096 combination chemotherapy Methods 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- AIUDWMLXCFRVDR-UHFFFAOYSA-N dimethyl 2-(3-ethyl-3-methylpentyl)propanedioate Chemical class CCC(C)(CC)CCC(C(=O)OC)C(=O)OC AIUDWMLXCFRVDR-UHFFFAOYSA-N 0.000 description 1
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000021312 gluten Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 201000003911 head and neck carcinoma Diseases 0.000 description 1
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- HHVIBTZHLRERCL-UHFFFAOYSA-N methylsulphonylmethane Natural products CS(C)(=O)=O HHVIBTZHLRERCL-UHFFFAOYSA-N 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 235000021239 milk protein Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 210000004237 neck muscle Anatomy 0.000 description 1
- 230000035407 negative regulation of cell proliferation Effects 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- DXGLGDHPHMLXJC-UHFFFAOYSA-N oxybenzone Chemical compound OC1=CC(OC)=CC=C1C(=O)C1=CC=CC=C1 DXGLGDHPHMLXJC-UHFFFAOYSA-N 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 229940066779 peptones Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000013587 production medium Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000029219 regulation of pH Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 108010046845 tryptones Proteins 0.000 description 1
- 230000004222 uncontrolled growth Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D223/08—Oxygen atoms
- C07D223/10—Oxygen atoms attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D223/12—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/10—Nitrogen as only ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
WO 2005/044803 PCT/EP2004/011244 BENGAMIDE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF FOR THE TREATMENT OF CANCER 5 Cancer is a disease of humans and animals which is for the most part fatal and which is caused by the uncontrolled growth of endogenous cells. Cancer is the term for the formation of malignant tumors (malignomas) and of neoplasms (tumors or carcinomas) or for the malignant degeneration and disturbed maturation of white blood cells (leukemia, blood cancer). 10 Cancer cells or tumor cells arise as the result of the transformation of endogenous cells. The malignancy of the cancer cell is expressed in the autonomy of its growth, that is in the ability of the cell to grow in an uninhibited manner and without being fitted into the structure of the organs and also to grow in an infiltrating manner, thereby destroying tissue. The 15 formation of disseminations (metastases) at a distance from the tumor, after tumor cells have been spread by way of the blood or the lymph, is a sure sign of malignancy. Cancer is one of the most frequent causes of death in humans and there is therefore a great need for methods and means for curing or treating malignant degenerations. 20 Aside from the, if possible radical, surgical removal of the tumor, the possibilities for treating malignant tumors include radiological therapy using X-rays, a-rays, p-rays and y-rays, immunotherapy and chemotherapy. At present, immunotherapy can only be used to a limited extent. The chemo 25 therapy of tumors is' understood as meaning the administration of cell poisons (cytostatic agents) for treating tumors and tumor cells which remain, usually following local surgical treatment or irradiation. These substances interfere specifically in certain processes in cell division, which means that tissues containing a high proportion of dividing cells, such as 30 rapidly growing tumor tissues, react more sensitively. The cytostatic agents which are used are alkylating compounds, such as cyclophosphamide, antimetabolites, such as methotrexate, alkaloids, such as vincristine, and antibiotics, such as daunomycin or adriamycin. However, due to massive side-effects, all these agents suffer from severe disadvantages, such that 35 the death of the affected patient is only delayed and not averted. Furthermore, the degenerate (cancer) cells develop resistances to the agents which are used; while the medicaments which are being used at the time then no longer have any cytostatic effect, they are still toxic as a 2 consequence of the side-effects. In addition, it has been found that the efficacy achieved by using cytostatic agents in combination or in sequence exceeds that achieved by using a single cytostatic agent (monotherapy) and, as a result, it is possible that the substantial side-effects are not 5 additive in connection with polychemotherapy. For all these reasons, novel chemotherapeutic agents are urgently required and are therefore being sought world-wide. The first examples of bengamides were bengamides A and B, which are 10 dodecanoyl-substituted on the caprolactam ring and which were isolated from the sea sponge Jaspis cf. Coriacea (family Coppatiidae, order Choristida B Astrophorida) (Adamczewski et al., J. Org. Chem. 1986, 51, 4497-4498) and reported to be biotoxic to eukaryotic cells, nematodes and bacteria. 15 Bengamide E H I 0 OH OH
N
OMe OH 20 and its N-methylated derivative bengamide F are examples of bengamide derivatives which have been demonstrated to possess antitumor activity. Bengamide E inhibits cell proliferation by stopping cell division at the G1/S restriction point and in the G2/M phase of the cell cycle. Bengamide B derivatives inhibit the proliferation of MDA-MB-435 breast cancer cells 25 (Kinder et al., J. Med. Chem. 2001, 44, 3692-3699). A feature shared in common by the known bengamide derivatives is that they have been isolated from sea sponges of the genus Jaspis sp. or Pachastrissa sp. (Thale et al., J. Org. Chem. 2001, 66, 1733-1741). 30 It has now been found that the microorganism strain Myxococcus virescens ST200611 (DSM 15898) is able to form novel bengamide derivatives which inhibit cell proliferation at low concentrations and are consequently suitable to be used for the treatment and/or prophylaxis of cancer diseases. 35 3 The present invention relates to a compound of the formula (I), R1 N 0 0
OR
3
OR
3 R2N Ole OR 3 (I 5 wherein R1 is H or (C1-C6)-alkyl,
R
2 is H or OH, and R3 is H or -C(=0)-(C1-C6)-alkyl, or to a physiologically tolerated salt of a compound of the formula (1). 10 Independently of each other, R 1 is preferably H or methyl and R 3 is preferably H. The invention preferably relates to a compound of the formula (1) in which 15 R1 is H or methyl, R2 is H or OH, and R3 is H.
(C
1
-C
6 )-Alkyl is a straight-chain or branched alkyl group having 6 carbon 20 atoms, for example methyl (Me), ethyl, n-propyl, iso-propyl, tert-butyl or n-hexyl, preferably methyl. In addition, the invention relates to a compound of the formula (1) which is characterized by a compound of the formula (II) 25 H 0 OH OH N H OMe OH (I), a compound of the formula (ll) 4 Me N 0 0 OH OH N H OMe OH(), and a compound of the formula (IV) H I O OH OH HO N OMe OH (IV). The present invention furthermore relates to all obvious chemical equivalents of the compounds of the formula (I) according to the invention. These equivalents are compounds which exhibit only a slight chemical 10 difference, and have the same pharmacological effect, or which are converted into the compounds according to the invention under mild conditions. Said equivalents also include, for example, salts, reduction products, oxidation products, esters, ethers, acetals or amides of the compounds of the formula (1) as well as equivalents which the skilled 15 person can prepare using standard methods and, in addition to this, all the optical antipodes and diastereomers and all the stereoisomeric forms. The invention also relates to a process for preparing a compound of the formula (V) 20
R
1 N 0 O OR 3
OR
3 R- R4 '2 H OMe OR 3 (V), wherein
R
1 is H or (C1-C6)-alkyl, 25 R 2 is H or OH, 5 R3 is H or -C(=O)-(C1-C6)-alkyl, and R4 is methyl or ethyl, or to a physiologically tolerated salt of a compound of the formula (V), 5 which comprises 1. the strain Myxococcus virescens ST200611 (DSM 15898), or one of its variants and/or mutants, being fermented under suitable conditions in a culture medium until one or more of the compounds of the formula (V) accrue(s) in the culture medium, 10 2. a compound of the formula (V) being isolated from the culture medium, and 3. the compound of the formula (V) being derivatized, where appropriate, and/or, where appropriate, being converted into a physiologically tolerated salt. 15 The invention preferably relates to a process for preparing a compound of the formula (V) where R 4 is ethyl. The product of such a process corresponds to a compound of the formula (I) as described above. 20 The invention particularly preferably relates to a process for preparing a compound of the formula (V) where, independently of each other, R1 is H or methyl, R3 is H and R4 is ethyl. In addition, the invention relates to a process for preparing a compound of 25 the formula (II), a compound of the formula (111) and a compound of the formula (IV) as well as the bengamide derivatives E and F. Unless otherwise indicated, the chiral centers in the compounds of the formula (1) and (V) can be present in the R configuration or in the S 30 configuration. The invention relates both to the optically pure compounds and to stereoisomeric mixtures, such as enantiomeric mixtures and diastereomeric mixtures. Physiologically tolerated salts of compounds of the formula (1) and (V) are 35 understood as being both their organic salts and their inorganic salts, as are described in Remington's Pharmaceutical Sciences (17th edition, page 1418 (1985)). Because of their physical and chemical stability and their solubility, sodium, potassium, calcium and ammonium salts are preferred, inter alia, for acid groups; salts of hydrochloric acid, sulfuric acid or 6 phosphoric acid, or of carboxylic acids or sulfonic acids, such as acetic acid, citric acid, benzoic acid, maleic acid, fumaric acid, tartaric acid and p-toluenesulfonic acid, are preferred, inter alia, for basic groups. 5 The culture medium is a nutrient solution or a solid medium containing at least one customary carbon source and nitrogen source as well as the customary inorganic salts. If hydroxylysine is added to the culture medium, the strain Myxococcus virescens ST200611 (DSM 15898) produces a compound of the formula (V) in which R 2 is OH as a result of digesting 10 hydroxylysine. One part of the subject matter of the present invention is therefore a process for preparing a compound of the formula (V) as described above where R 2 is OH and where the culture medium in step 1 contains hydroxy 15 lysine. The process according to the invention can be used for fermenting on a laboratory scale (milliliter to liter scale) and for fermenting on an industrial scale (cubic meter scale). 20 Suitable carbon sources for the fermentation are assimilable carbohydrates and sugar alcohols, such as glucose, lactose, sucrose or D-mannitol, as well as carbohydrate-containing natural products, such as malt extract or yeast extract. Examples of nitrogen-containing nutrients are amino acids; 25 peptides and proteins and also their breakdown products, for example casein, peptones or tryptones; meat extracts; yeast extracts; gluten; ground seeds, for example from corn, wheat, beans, soya or the cotton plant; distillation residues from producing alcohol; meat meals; yeast extracts; ammonium salts; nitrates. Preference is given to the nitrogen source being 30 one or more peptide(s) which has/have been obtained synthetically or biosynthetically. Examples of inorganic salts are chlorides, carbonates, sulfates or phosphates of the alkali metals, the alkaline earth metals, iron, zinc, cobalt and manganese. Examples of trace elements are cobalt and manganese. 35 Conditions which are suitable for forming the bengamides according to the invention are as follows: the bengamides according to the invention are preferably formed in a culture medium which contains from 0.05 to 5%, preferably from 0.1 to 2.5%, yeast extract; from 0.2 to 5.0%, preferably 7 from 0.1 to 2%, casitone; from 0.02 to 1.0%, preferably from 0.05 to 0.5%, CaCl2 x 2 H20; from 0.02 to 1.5%, preferably from 0.05 to 0.7%, MgSO4 x 7 H 2 0 and from 0.00001% to 0.001% cyanocobalamin. The percentage values which are given are in each case based on the weight of the total 5 nutrient solution. The microorganism is cultured aerobically, that is, for example, submerged while being shaken or stirred in shaking flasks or fermenters, or on solid medium, where appropriate while air or oxygen is being passed in. The 10 microorganism can be cultured in a temperature range of from about 18 to 350C, preferably at from about 20 to 320C, in particular at from 27 to 300C. The pH range should be between 4 and 10, preferably between 6.5 and 7.5. The microorganism is generally cultured under these conditions for a period of from 2 to 10 days, preferably of from 72 to 168 hours. The micro 15 organism is advantageously cultured in several steps, i.e. one or more preliminary cultures are initially prepared in a liquid nutrient medium, with these preliminary cultures then being inoculated into the actual production medium, i.e. the main culture, for example in a ratio by volume of from 1:10 to 1:100. The preliminary culture is obtained, for example, by inoculating 20 the strain, in the form of vegetative cells or fruiting bodies, into a nutrient solution and allowing it to grow for from about 20 to 120 hours, preferably for from 48 to 96 hours. Vegetative cells and/or fruiting bodies can be obtained, for example, by allowing the strain to grow for from about 1 to 15 days, preferably for from 4 to 10 days, on a solid or liquid nutrient 25 substrate, for example yeast agar. A bengamide derivative of the formula (V) is isolated or purified from the culture medium using known methods and taking account of the chemical, physical and biological properties of the natural substances. HPLC was 30 used to test the concentrations of the respective bengamide derivatives in the culture medium or in the individual isolation steps, with the quantity of the substance formed expediently being compared with a calibration solution. 35 For the isolation, the culture broth or the culture together with the solid medium is lyophilized, after which the bengamide derivatives are extracted from the lyophilizate using an organic solvent, for example methanol or 2-propanol. The organic solvent phase contains the natural substances 8 according to the invention; it is concentrated, where appropriate, in vacuo and subjected to further purification. The further purification of one or more compounds according to the 5 invention is effected by chromatography on suitable materials, preferably, for example, on molecular sieves, on silica gel, on aluminum oxide, on ion exchangers or on adsorber resins or on reversed phases (RPs). This chromatography is used to separate the bengamide derivatives. The bengamide derivatives are chromatographed using buffered aqueous 10 solutions or mixtures of aqueous and organic solutions. Mixtures of aqueous or organic solutions are understood as being all water miscible organic solvents, preferably methanol, 2-propanol or acetonitrile, at a concentration of from 5 to 95% solvent, preferably from 5 to 40% 15 solvent, or else all buffered aqueous solutions which are miscible with organic solvents. The buffers which are to be used are the same as specified above. The bengamide derivatives are separated, on the basis of their differing 20 polarities, by means of reversed phase chromatography, for example on MCI® (adsorber resin from Mitsubishi, Japan) or Amberlite XAD® (TOSOHAAS), or on other hydrophobic materials, for example on RP-8 or RP-18 phases. In addition, the separation can be effected by means of normal-phase chromatography, for example on silica gel, aluminum oxide 25 and the like. The bengamide derivatives are chromatographed using buffered, basic or acidified aqueous solutions or mixtures of aqueous solutions with alcohols or other water-miscible organic solvents. Preference is given to using 30 acetonitrile and methanol as organic solvent. Buffered, basic or acidified aqueous solutions are understood as being, for example, water, phosphate buffer, ammonium acetate and citrate buffer at a concentration of up to 0.5 M, as well as formic acid, acetic acid, trifluoro 35 acetic acid, ammonia and triethylamine, or all commercially available acids and bases known to the skilled person, preferably at a concentration of up to 1%. In the case of buffered aqueous solutions, particular preference is given to 0.1% ammonium acetate.
9 The chromatography was carried out using a gradient which began with 100% water and ended with 100% solvent; the chromatography was preferably run with a linear gradient of from 5 to 95% acetonitrile. 5 Alternatively, it is also possible to carry out a gel chromatography or chromatography on hydrophobic phases. The gel chromatography is carried out on polyacrylamide gels or copolymer gels, such as Biogel-P 2® (Biorad) or Fractogel TSK HW 400 (Merck, Germany). The sequence of the abovementioned chromatographic steps can be reversed. 10 Insofar as bengamides are present as diastereomers, they can be separated using known methods, for example by means of separation using a chiral column. 15 The derivatization of the OH groups in the side chain of the compounds of the formulae (1) and/or (V) (R 3 is in each case H) to give an acyl group (R 4 is in each case -C(=O)-(C 1
-C
6 )-alkyl) is effected using methods which are known per se (J. March, Advanced Organic Chemistry, John Wiley & Sons, 4th edition, 1992), for example by means of reaction with an acid 20 anhydride. For example, Adamczeski et al., J. Am. Chem. Soc. 1989, 111, 647-654 describe the reaction with acetic anhydride to give a compound of the formula (1) and/or (V) in which R3 is -C(=O)-CH3. The alkylation of the NH group in the caprolactam ring of a compound of 25 formula (1) or (V) (R1 is in each case H) is likewise effected using methods which are known per se (J. March, Advanced Organic Chemistry, John Wiley & Sons, 4th Edition, 1992), for example by reaction with Me2CO3 or Me2SO4, to prepare the corresponding N-methylated derivatives, or by reaction with (C 1
-C
6 )-alkyl bromide in the presence of a base. 30 An isolate of the microorganism strain Myxococcus virescens ST200611 was deposited in the Deutschen Sammlung von Mikroorganismen und Zellkulturen [German Collection of Microorganisms and Cell Cultures] GmbH (DSMZ), Mascheroder Weg 1B, 38124 Brunswick, Germany, in 35 accordance with the rules of the Budapest treaty, on 11.09.2003 under the following number: DSM 15898.
10 The vegetative cells of the strain DSM 15898 have the rod form which is characteristic for Myxococcus virescens. On solid nutrient substrates, Myxococcus virescens ST200611 (DSM 15898) forms orange-yellow fruiting bodies which contain round myxospores. 5 Instead of the strain Myxococcus virescens ST200611 (DSM 15898), it is also possible to use its mutants and/or variants which synthesize one or more of the compounds according to the invention. 10 A mutant is a microorganism in which one or more genes in the genome has/have been modified, with the gene, or the genes, which is/are responsible for the ability of the organism to produce the compound according to the invention remaining functional and heritable. 15 Such mutants can be produced, in a manner known per se, using physical means, for example irradiation, as with ultraviolet rays or X-rays, or chemical mutagens, such as ethyl methanesulfonate (EMS); 2-hydroxy 4-methoxybenzophenone (MOB) or N-methyl-N'-nitro-N-nitrosoguanidine (MNNG), or as described by Brock et al. in "Biology of Microorganisms", 20 Prentice Hall, pages 238-247 (1984). A variant is a phenotype of the microorganism. Microorganisms have the ability to adapt to their environment and therefore exhibit highly developed physiological flexibility. All the cells of the microorganism are involved in the 25 phenotypic adaptation, with the nature of the change not being genetically conditioned and being reversible under altered conditions (H. Stolp, Microbial ecology: organism, habitats, activities. Cambridge University Press, Cambridge, GB, page 180, 1988). 30 Screening for mutants and/or variants which synthesize one or more of the compounds according to the invention takes place in accordance with the following scheme: - lyophilizing the fermentation medium; - extracting the lyophilizate with an organic solvent 35 - extracting the compound from the culture filtrate using solid phases - analyzing by means of HPLC or TLC or by testing the biological activity.
11 The fermentation conditions which have been described apply for Myxo coccus virescens ST200611 (DSM 15898) and for mutants and/or variants thereof. 5 The present invention also relates to the use of the microorganism Myxococcus virescens ST200611 (DSM 15898), or of a mutant and/or variant, for preparing a compound of the formula (V), in particular a compound of the formula (IV), or a physiologically tolerated salt thereof, as described above. 10 A test which is based on determining the intracellular concentration of ATP is employed for detecting the inhibition of cell proliferation. It is possible to use known tumor cell lines such as Hep-G2 and Colo205. In this test, the ATP content of metabolically active cells serves, in a luciferase reaction, as 15 a measure of the number of living cells. The compounds of the formula (ll)-(VI) were used in the test in a single dose of 0.3 - 40 pM and a dose dependency given as a TC50 value, with (IIA) and (11B) in each case denoting a diastereomer of the compound of 20 the formula (11): Table 1: Activity of the bengamides in a cell proliferation test, expressed as TC50 value in piM Compound Hep-G2 Colo 205 (1l) 16 27 (IIA) 17 33 (IIB) 6 10 (Il1) 9 15 (IV) >40 42 Bengamide E 36 46 Bengamide F 27 33 The invention therefore also relates to the use of the compound of the formula (1) or of a physiologically tolerated salt thereof as a pharmaceutical 25 in human or animal medicine, in particular for the treatment and/or 12 prophylaxis of cancer diseases. The invention preferably relates to the use of a compound of the formula (1), or of a physiologically tolerated salt, for treating breast cancer, intestinal cancer, stomach cancer, liver cancer, brain tumors, ovarial tumors, esophageal cancer, renal cancer and muscle 5 cell carcinoma, in particular carcinoma of the head and neck muscles. In addition, the present invention relates to a pharmaceutical having a content of at least one compound of the formula (1) or of a physiologically tolerated salt thereof, with it being possible for the compound or the 10 compounds of the formula (1) to be administered as such or, preferably, to be present in a mixture with one or more of the customary, pharma cologically suitable carrier substances or auxiliary substances. The compounds according to the invention are stable in the solid state and 15 in solutions in a pH range of between 2 and 9, in particular 5 and 7, and, as a consequence, can be incorporated into customary galenic preparations. While the pharmaceuticals according to the invention can be administered orally or parenterally, a rectal use is also possible in principle. Examples of 20 suitable solid or liquid galenic preparation forms are granules, powders, tablets, sugar-coated tablets, (micro)capsules, suppositories, syrups, emulsions, suspensions, aerosols, drops or injectable solutions in ampoule form, as well as preparations giving a protracted release of active compound, in connection with whose preparation use is customarily made 25 of pharmacologically suitable carrier substances or auxiliary substances, such as disintegrants, binders, coating agents, swelling agents, glidants, lubricants, flavoring substances, sweeteners or solubilizers, for example magnesium carbonate, titanium dioxide, lactose, mannitol and other sugars, talc, milk protein, gelatin, starch, vitamins, cellulose and its 30 derivatives, animal or vegetable oils, polyethylene glycols and solvents, such as sterile water, alcohols, glycerol and polyhydric alcohols. Where appropriate, the dosage units for oral administration can be micro encapsulated in order to delay release or to extend it over a relatively long 35 period, for example by means of coating or embedding the active compound in particle form in suitable polymers, waxes or the like. Preference is given to producing and administering the pharmaceutical preparations in dosage units, with each unit containing, as the active 13 constituent, a defined dose of one or more compounds of the bengamide derivatives of the formula (1). In the case of solid dosage units such as tablets, capsules and suppositories, this dose can be up to about 500 mg, preferably, however, from about 0.1 to 200 mg, and, in the case of injection 5 solutions in ampoule form, up to about 200 mg, preferably, however, from about 0.5 to 100 mg, per day. The daily dose which is to be administered depends on the bodyweight, age, sex and condition of the mammalian subject. However, higher or lower 10 daily doses may also possibly be appropriate. The daily dose can be administered both by means of once-only administration in the form of a single dosage unit, or else in several smaller dosage units, and by means of the multiple administration of subdivided doses at defined intervals. 15 The pharmaceuticals according to the invention are produced by bringing one or more of the compounds of the formula (1) according to the invention into a suitable form for administration, optionally together with one or more of the customary carrier substances or auxiliary substances. 20 The following examples are intended to explain the invention in more detail without limiting its scope in any way. Unless otherwise indicated, percentage values refer to the weight and mixing ratios in the case of liquids refer to the volume. 25 Example 1: Storing Myxococcus virescens ST200611 (DSM 15898) at -135 0 C An agar plate (1% fresh baker's yeast, 1% CaC12 x 2 H20, 20 mM HEPES, 30 0.00005% cyanocobalamin, 1.5% agar, pH 7.2) is inoculated with the strain Myxococcus virescens ST200611 (DSM 15898) and incubated at 300C for approx. 7 days. The cells in this surface culture are scratched off the agar surface using a sterile spatula, resuspended in 0.5 ml of casitone medium (1% casitone (Difco), 0.15% MgSO4 x 7 H 2 0, pH 7.0) and stored at 35 -135*C.
14 Example 2: Preparing a preliminary culture of Myxococcus virescens ST200611 (DSM 15898) in an Erlenmeyer flask 100 ml of nutrient solution (1% fresh baker's yeast, 1% CaC12 x 2 H20, 5 20 mM HEPES, 0.00005% cyanocobalamin, pH 7.2) in a sterile 300 ml Erlenmeyer flask are inoculated with the strain Myxococcus virescens ST20061 1 (DSM 15898) and the culture is incubated for 4 days at 300C and 180 rpm on a rotating shaker. 5 ml of this preliminary culture are then used for preparing the main cultures. 10 Example 3: Preparing a liquid main culture of Myxococcus virescens ST200611 (DSM 15898) A sterile 300 ml Erlenmeyer flask containing 100 ml of the following nutrient 15 solution (0.5% yeast extract, 0.5% casitone, 0.1% CaC12 x 2 H 2 0, 0.2% MgSO4 x 7 H20, 0.00005% cyanocobalamin, pH 7.4) is inoculated with 5 ml of a preliminary culture (see example 2), or a culture which has grown on a fresh agar plate (1% fresh baker's yeast, 1% CaC12 x 2 H20, 20 mM HEPES, 0.00005% cyanocobalamin, pH 7.2, plus 1.5% agar), and 20 incubated at 300C and 180 rpm on a shaker. The maximum production of the bengamides according to the invention is reached after 72-96 hours. A 72-96 hour-old submerged culture (inoculation quantity approx. 5-10%) from the same nutrient solution as described in example 2 is sufficient for inoculating from 10 to 200 I fermenters. 25 Example 4: Preparing a liquid main culture of Myxococcus virescens ST200611 (DSM 15898) while feeding in hydroxylysine for producing the bengamide derivative (IV) 30 A sterile 300 ml Erlenmeyer flask containing 100 ml of the following nutrient solution (0.5% yeast extract, 0.5% casitone, 0.1% CaC12 x 2 H20, 0.2% MgSO4 x 7 H20, 0.00005% cyanocobalamin and also 1 mM hydroxylysine pH 7.4) is inoculated with 5 ml of a preliminary culture from example 2 or a culture which has grown on a fresh agar plate (1% fresh baker's yeast, 1% 35 CaC12 x 2 H20, 20 mM HEPES, 0.00005% cyanocobalamin, pH 7.2, plus 1.5% agar) and incubated at 300C and 180 rpm on a shaker. The maximum production of the bengamide derivative (IV) is reached after 72-96 hours. HPLC-MS was used for the analysis. A 72-96 hour-old submerged culture 15 (inoculation quantity, approx. 5-10%) from the same nutrient solution as described in example 2 is sufficient for inoculating 10 to 200 I fermenters. Example 5: Preparing bengamide derivatives in a fermenter 5 The 10 I and 30 I fermenters were operated under the following conditions: Inoculum: approx. 5% approx. 9% Fermenter: 30 1 10 1 10 Nutrient medium: see example 2 see example 2 Incubation temperature: 30 0 C 30 0 C Stirrer speed: 112 rpm 150 rpm Aeration: 8 I/min 4 1/min pH regulation: from pH 7.8 to pH 7.5 from pH 8.1 to pH 7.5 15 p02 regulation: none none The pH was always regulated using 10% KOH or, respectively, 10%
H
2 SO4. Foam formation can be suppressed by repeatedly adding Clerol FBA 265 (Cognis Deutschland GmbH). Maximum production is reached 20 after approx. 72 to 96 hours. Example 6: Isolating bengamide derivatives (11) and (111), as well as bengamides E and F, from the shaken cultures of Myxococcus virescens ST200611 (DSM 15898) 25 After the Myxococcus virescens ST200611 (DSM 15898) fermentation had come to an end, the culture broth from example 3 (30 I culture broth), together with the biomass, was lyophilized and the lyophilizate was extracted with methanol (2 x 5 I). The methanol extract was reduced to 1.2 1 30 under vacuum and then loaded onto a prepared column which was packed with approx. 1.5 liters of CHP-20P material (MCI gel, 75-150 pL, Mitsubishi Chemical Corporation). The column was eluted with 95% methanol. The column flowthrough (120 ml/min) was collected and reduced down to a volume of 1.5 I in vacuo.
16 Example 7: Preseparating bengamide derivatives (II) and (III), and also bengamides E and F, by means of RP-18 chromatography 1.5 I of the solution obtained as described in example 6 were loaded onto a 5 Phenomenex Luna® 10 p C18 (2) column (size: 50 mm x 250 mm) possessing a Luna 10 ip C18 (2) precolumn (dimension: 21.2 mm x 60 mm) and eluted (0.1% ammonium acetate, pH 4.6, adjusted with acetic acid) over 60 min using a gradient of from 5% to 95% acetonitrile in water. The flow rate was 150 ml/min and the fraction size was 200 ml. 10 Bengamides were present in fractions 5-9, 10-11 and 12-14. Example 8: Purifying bengamide derivatives (II) and (111) and also bengamides E and F 15 The individual fractions from example 7 were lyophilized and purified once more by means of HPLC on a Phenomenex Luna® 10 pm C18 (2) column (dimension: 21 mm x 250 mm) possessing an XTerra® Prep MS C18 10 pm (Waters, dimension: 19 x 10 mm) precolumn. The column was eluted using a gradient of from 5% to 40% acetonitrile in water over 40 min 20 (in the added presence of 0.1% ammonium acetate, pH 8.8, adjusted with triethylamine). The column flowthrough (50 ml/min) was collected in fractions (7.5 ml fractions in each case). Fractions 5-9 from example 7 contained the compound of the formula (Ill) and, after chromatography and lyophilization, yielded 86 mg of bengamide E (purity > 95%). After chroma 25 tography, fractions 10-11 from example 7 yielded 145 mg of bengamide (11) (purity > 95%, 70/30 diastereomeric mixture) and 5 mg of bengamide F (purity > 95%). 35 mg of bengamide (Ill) (purity > 95%) were obtained as a diastereomeric mixture, in a 75:25 ratio, from fractions 12-14 from example 7. The diastereomers are in. each case the corresponding C-16 30 epimers. Example 9: Isolating the hydroxybengamide (IV) from the shaken cultures of Myxococcus virescens ST200611 (DSM 15898) 35 After the Myxococcus virescens ST200611 (DSM 15898) fermentation had come to an end, the culture broth from example 5 (10 I of culture broth), together with the biomass, was lyophilized and the lyophilizate was extracted with methanol (2 x 3 I). The methanol extract was reduced under 17 vacuum to 400 ml and then loaded onto a prepared column which had been packed with 0.6 liter of CHP-20P (MCI gel, 75-150 p, Mitsubishi Chemical Corporation) material. The column was eluted with 5% to 95% methanol in water. The column flowthrough (100 ml/min) was collected in 5 fractions over 60 min (0.5 min per fraction). The fractions containing the desired derivative (fractions 45-109) were pooled and reduced in vacuo down to a volume of 700 ml. Example 10: Prepurifying the hydroxybengamide (IV) by means of RP-18 10 chromatography The solution from example 9 was then loaded onto a Phenomenex Luna® 10 p C18 (2) column (size: 50 mm x 250 mm) possessing a Phenomenex Luna 10 lp C18 (2) precolumn (dimension: 21.2 mm x 60 mm) and eluted 15 (0.1% ammonium acetate, pH 8.8, adjusted with triethylamine) using a gradient of from 5% to 40% acetonitrile in water over 60 min. The flow rate was 150 ml/min and the fraction size was 225 ml. Fraction 22 contained the desired bengamide derivative. 20 Example 11: Purifying the hydroxybengamide (IV) Fraction 22 from example 10 was lyophilized and purified once again by means of HPLC on a Phenomenex Luna® 10 pm C18 (2) column (dimension: 21 mm x 250 mm) possessing a Waters XTerra Prep MS C18 25 10 pm precolumn (dimension: 19 x 10 mm). The column was eluted with a gradient of from 5% to 95% acetonitrile in water over 60 min (in the added presence of 0.1% ammonium acetate, pH 4.6, adjusted with acetic acid). The column flowthrough (50 ml/min) was collected in fractions (7.5 ml fractions in each case). The bengamide-containing fractions (fractions 26 30 28) were combined, desalted and freeze-dried. In connection with this, 7 mg of bengamide (IV) were obtained as a diastereomeric mixture in a ratio of 75:25. Example 12: Characterizing the compound of the formula (11) 35 Empirical formula: C 18
H
32
N
2 0 6 Molecular weight: 372.47 Diastereomeric mixture: 75:25 18 H 1 0 3 N 0 OH OH Postio 7H 13C 110- 1 7 16 44 1.412 287 N 9 13 15 17 H 1 6 OMe H0e357 Table 2: NMR-chemical shifts of bengamide (11), diastereomeric mixture, c =3 mg/mI in DMSO, 300 K. Position 1 13 1 3 173.99 2 7.91 3 3.19/3.06 40.56 4 1.74/1.20 28.75 5 1.87/1.64 27.55 6 1.87/1.36 30.72 7 4.39 51.27 8 7.78 9 -169.61 10 3.69 81.60 10O-OMe 3.25 57.32 11 3.58 70.72 11-OH 4.46 12 3.33 72.80 12-OH 4.36 13 3.97 72.46 13-OH 4.56 14 5.37 129.05 15 5.48 136.57 16 1.99 37.41 16-Me 0.93 19.90 17 1.26 29.15 19 18 0.81 11.58 20 Example 13: Characterizing the compound of the formula (111) Empirical formula: C 19
H
34
N
2 0 6 Molecular weight: 386.49 5 Diastereomeric mixture: 75/25 Table 3: NMR-chemical shifts of bengamide (Ill), diastereomeric mixture, c = 3 mg/ml in DMSO, 300 K. Position 1H 13C 1 - 171.95 2 2.91 35.28 3 3.61/3.21 49.20 4 1.71/1.31 26.13 5 1.82/1.67 27.11 6 1.84/1.32 30.80 7 4.55 51.14 8 7.84 9 - 169.54 10 3.69 81.55 10-OMe 3.25 57.28 11 3.57 70.69 11-OH 4.45 12 3.33 72.77 12-OH 4.37 13 3.97 72.47 13-OH 4.56 14 5.37 129.04 15 5.48 136.58 16 1.99 37.41 16-Me 0.93 19.89 17 1.26 29.15 18 0.81 11.58 21 Example 14: Characterizing the compound of the formula (IV) Empirical formula: C 18
H
32
N
2 0 7 Molecular weight: 388.46 5 Diastereomeric mixture: 75/25 Table 4: NMR-chemical shifts of bengamide (IV), diastereomeric mixture, c = 3.1 mg/ml in DMSO, 300 K. Position 1H 13C 1 - 173.45 2 7.55 3 3.35/3.02 45.05 4 3.74 63.48 4-OH 4.60 5 1.81/1.75 34.28 6 1.68/1.64 24.25 7 4.32 51.18 8 7.77 9 - 169.63 10 3.70 81.59 10-OMe 3.26 57.30 11 3.58 70.73 11-OH 4.47 12 3.34 72.82 12-OH 4.38 13 3.97 72.47 13-OH 4.56 14 5.37 129.06 15 5.48 136.57 16 1.99 37.41 16-Me 0.93 19.90 17 1.26 29.15 18 0.81 11.58 22 Example 15: Characterizing bengamide E Empirical formula: C 17
H
30
N
2 0 6 Molecular weight: 358.44 5 Table 5: NMR-chemical shifts of bengamide E, c = 3 mg/ml in DMSO, 300 K. Position 1H 13C 1 - 174.01 2 7.91 3 3.19/3.06 40.56 4 1.74/1.20 28.75 5 1.87/1.64 27.56 6 1.87/1.36 30.72 7 4.39 51.27 8 7.78 9 - 169.60 10 3.69 81.61 10-OMe 3.25 57.30 11 3.56 70.74 11-OH 4.49 12 3.33 72.78 12-OH 4.38 13 3.96 72.38 13-OH 4.57 14 5.38 127.68 15 5.58 137.85 16 2.24 30.08 17 0.95 22.27 18 0.95 22.17 23 Example 16: Characterizing bengamide F Empirical formula: C 18
H
32
N
2 0 6 Molecular weight: 372.47 5 Table 6: NMR-chemical shifts of bengamide F, c = 3 mg/ml in DMSO, 300 K. Position H 2 2.91 3 3.62/3.21 4 1.69/1.33 5 1.84/1.69 6 1.84/1.33 7 4.56 8 7.84 9 10 3.70 10-OMe 3.25 11 3.57 12 3.33 13 3.97 14 5.38 15 5.59 16 2.25 17 0.95 18 0.95 Example 17: Separating the diastereomers of compound (II) The diastereomeric mixture of the compound of formula (II) from example 8 10 was seperated on a chiral column (AD/H, Daicel, 20 x 200 mm, 0.5 ml flow, mobile phase: acetonitrile:methanol 4:1 + 0.1% NH4Ac). The optical purity 24 was checked on an analytical AD/H column (Daicel) (4.6 x 250 mm, 30*C, mobile phase: acetonitrile:methanol 4:1 + 0.1% NH 4 Ac, 0.75 ml flow, Rt peak: 9.9 min, Rt peak2: 10.9 min). Table 7: NMR-chemical shifts of the diastereomers of bengamide (II), c = 3 mg/ml in DMSO, 300 K. 1 H (A) H (B) 13C (A) 13C (B) 1 - - 173.99 173.99 2 7.91 7.91 - 3 3.19/3.06 3.19/3.06 40.56 40.56 4 1.74/1.20 1.74/1.20 28.75 28.75 5 1.87/1.64 1.87/1.64 27.55 27.55 6 1.87/1.36 1.87/1.36 30.72 30.72 7 4.39 4.39 51.27 51.27 8 7.78 7.78 - 9 - - 169.61 169.61 10 3.69 3.69 81.60 81.60 10-OMe 3.25 3.25 57.32 57.32 11 3.58 3.58 70.72 70.77 11-OH 4.46 4.47 - 12 3.33 3.33 72.80 72.85 12-OH 4.36 4.36 - 13 3.97 3.97 72.46 72.37 13-OH 4.56 4.56 - 14 5.37 5.38 129.05 129.01 15 5.48 5.49 136.57 136.44 16 1.99 1.99 37.41 37.28 16-Me 0.93 0.92 19.90 19.86 17 1.26 1.26 29.15 29.06 18 0.81 0.82 11.58 11.48 25 Example 18: Cell proliferation measurements performed on various tumor cell lines The tumor cell lines Hep-G2 (ATCC No. HB-8065) and COLO 205 (ATCC 5 No. CCL-222) were used for determining the cell proliferation. The cell lines were sown in cell culture medium at the rate of 1000 cells/well [Hep-G2] and, respectively, 3500 cells/well [Colo205] and incubated for 4 hours at 370C and 5% CO2. 10 Medium for Hep-G2: Dulbecco's modified Eagle's medium / Ham's F12 mix (Gibco); NEAA (10%; nonessential amino acids, Gibco), sodium pyruvate (1%, Gibco), L-glutamine (1%, Gibco), fetal calf serum (5%; PAA)]. Medium for COLO 205: RPMI 1640 (Gibco), L-glutamine (1%, Gibco), 15 HEPES (1%, Gibco), fetal calf serum (10%, PAA). After 4 hours, compounds (II), (111) and (IV) and bengamides E and F, dissolved in DMSO/cell culture medium, were added at various dilutions and the mixtures were incubated for 72 hours at 370C and 5% C02. The 20 intracellular content of ATP was determined using the test reagent CellTiterGlo (Promega). The results of the cell proliferation tests are reported in table 1.
la) o EL C0 >. 0' CC C: *53 .0)U Eu CD 400 Cto 0 c LO Co C 25b Table 8 shows the activity of the compounds of the formulae (II) and (111) in a cell proliferation (MTS) assay against a variety of cancer cell lines in comparison to the known compound Bengamide E. 5 As can be seen, compounds (11) and (Ill) exhibit improved inhibitory activity against all tested cell lines. This result is unexpected since the structural difference between the tested compounds lies in an additional methylene group in the side-chain only (10 carbon atoms instead of 9 carbon atoms). 10 Comprises/comprising and grammatical variations thereof when used in this specification are to be taken to specify the presence of stated features, integers, steps or components or groups thereof, but do not preclude the presence or addition of one or more other features, integers, steps, components or groups 15 thereof.
Claims (14)
1. Use of a compound of the formula (11) H N OHOH OMe OH (11), 5 or a physiologically tolerated salt thereof, in the manufacture of a medicament.
2. Use of a compound of the formula (111) Me N 0 0 OH OH N H OMe OH (1l1), 10 or a physiologically tolerated salt thereof, in the manufacture of a medicament.
3. A pharmaceutical composition comprising a compound or salt according to claim I or 2, or a mixture thereof, and a pharmaceutically acceptable excipient. 27
4. A process for preparing a compound of the formula (V) 1V) N O O OR3 OR3 wherein R1 is H or (C1-C 6 )-alkyl, 5 R 2 isHorOH, R 3 is H or -C(=O)-(Cr-C)-alkyl, and R 4 is methyl or ethyl or a physiologically tolerated salt of a compound of the formula (V), 0 which comprises 1. the strain Myxococcus virescens ST20011 (OSM 15898), or one of its variants and/or mutants, being fermented under suitable conditions in a culture medium until one or more of the compounds of the formula (V) accrues) in the culture 15 medium, 2. a compound of the formula (V) being isolated from the culture medium, and 3. the compound of the formula (V) being derivatized and/or converted into a physiologically tolerated salt, where 20 appropriate, wherein said compound or salt is used in the manufacture of a medicament.
5. The process as claimed in claim 4, wherein R4 is ethyl. 28
6. The process as claimed in claim 4 or 5 wherein, independently of each other, R 1 is H or methyl, R 3 is H and R 4 of ethyl.
7. The process as claimed in any one of claims 4 to 6, wherein R 2 is OH and wherein the culture medium contains hydroxylysine. 5
8. The microorganism Myxococcus virescens ST200611 (DSM 15898).
9. The use of microorganism Myxococcus virescens ST200611 (DSM 15898), or of a mutant and/or variant thereof, in preparing a compound of the formula (V) R1 R OMe O R3 (V), 0 wherein R 1 is H or (C-C 6 )-alkyl, R 2 is H or OH, R 3 is H or -C(=O)-(C-C6)-alkyl, and R 4 is methyl or ethyl 15 or a physiologically tolerated salt thereof, wherein said compound or salt is used in the manufacture of a medicament.
10. A method of treatment and/or prophylaxis of cancer disease wherein a subject in need is administered an effective amount of the medicament of claim 1 or 2, the pharmaceutical composition of claim 3, or a compound of 29 the formula (V) or a physiological salt thereof when prepared by the process of any one of claims 4 to 6.
11. The use of claim 1 or 2 substantially as hereinbefore described.
12. A pharmaceutical composition according to claim 3 substantially as 5 hereinbefore described.
13. The process of any one of claims 4 to 6 substantially as hereinbefore described.
14. The use according to claim 9 substantially as hereinbefore described. 10 SANOFI-AVENTIS DEUTSCHLAND GMBH WATERMARK PATENT & TRADE MARK ATTORNEYS P26877AU00
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10349669.6 | 2003-10-24 | ||
DE10349669A DE10349669B3 (en) | 2003-10-24 | 2003-10-24 | Bengamide derivatives, process for their preparation and their use |
PCT/EP2004/011244 WO2005044803A1 (en) | 2003-10-24 | 2004-10-08 | Bengamide derivatives, method for the production thereof and use thereof for the treatment of cancer |
Publications (2)
Publication Number | Publication Date |
---|---|
AU2004287561A1 AU2004287561A1 (en) | 2005-05-19 |
AU2004287561B2 true AU2004287561B2 (en) | 2011-06-02 |
Family
ID=34484998
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2004287561A Expired - Fee Related AU2004287561B2 (en) | 2003-10-24 | 2004-10-08 | Bengamide derivatives, method for the production thereof and use thereof for the treatment of cancer |
Country Status (30)
Country | Link |
---|---|
EP (2) | EP1680405B1 (en) |
JP (1) | JP4769190B2 (en) |
KR (1) | KR20060120044A (en) |
CN (2) | CN100398520C (en) |
AR (1) | AR046553A1 (en) |
AT (2) | ATE477244T1 (en) |
AU (1) | AU2004287561B2 (en) |
BR (1) | BRPI0415529A (en) |
CA (1) | CA2543003A1 (en) |
CL (1) | CL2009000674A1 (en) |
CY (1) | CY1110458T1 (en) |
DE (3) | DE10349669B3 (en) |
DK (1) | DK1680405T3 (en) |
ES (1) | ES2320894T3 (en) |
HK (1) | HK1098131A1 (en) |
HR (1) | HRP20090187T1 (en) |
IL (1) | IL174524A (en) |
MA (1) | MA28213A1 (en) |
ME (1) | MEP33108A (en) |
MX (1) | MXPA06004084A (en) |
NO (1) | NO20062149L (en) |
NZ (1) | NZ546744A (en) |
PL (1) | PL1680405T3 (en) |
PT (1) | PT1680405E (en) |
RS (1) | RS20060263A (en) |
RU (1) | RU2357956C2 (en) |
SI (1) | SI1680405T1 (en) |
UY (1) | UY28574A1 (en) |
WO (1) | WO2005044803A1 (en) |
ZA (1) | ZA200602231B (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2878525B1 (en) * | 2004-11-29 | 2007-02-23 | Aventis Pharma Sa | BENGAMIDES HAVING SUBSTITUTED CAPROLACTAM CYCLE, PREPARATION METHOD, COMPOSITIONS CONTAINING SAME AND USE THEREOF |
FR2878528B1 (en) | 2004-11-29 | 2008-05-16 | Aventis Pharma Sa | 2-ALCOXY-3,4,5-TRIHYDROXY-ALKYLAMIDES, PREPARATION THEREOF, COMPOSITIONS CONTAINING SAME AND USE THEREOF |
FR2901554B1 (en) | 2006-05-24 | 2011-04-01 | Sanofi Aventis | 2-ALCOXY-3,4,5-TRIHYDROXY-ALKYLAMIDE-BENZAZEPINE, PREPARATION THEREOF, COMPOSITIONS CONTAINING SAME AND USE THEREOF |
FR2901556A1 (en) | 2006-05-24 | 2007-11-30 | Sanofi Aventis Sa | 2-ALCOXY-3,4,5-TRIHYDROXY-ALKYLAMIDE DERIVATIVES, THEIR PREPARATION, COMPOSITIONS CONTAINING SAME AND USE THEREOF |
FR2901555A1 (en) | 2006-05-24 | 2007-11-30 | Sanofi Aventis Sa | 2-ALCOXY-3,4,5-TRIHYDROXY-ALKYLAMIDE-BENZOTHIAZEPINE, THEIR PREPARATION, COMPOSITIONS CONTAINING SAME AND USE THEREOF |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CO5140099A1 (en) * | 1998-11-17 | 2002-03-22 | Novartis Ag | CERTAIN SUBSTITUTED CAPROLACTAMAS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND ITS USE IN TUMORS TREATMENT |
JP2003532711A (en) * | 2000-05-11 | 2003-11-05 | ノバルティス アクチエンゲゼルシャフト | Substituted caprolactam carbonates and caprolactam ethers and their use as antitumor agents |
JP2004262793A (en) * | 2003-02-28 | 2004-09-24 | Noyaku Bio Technology Kaihatsu Gijutsu Kenkyu Kumiai | Compound n-9011, its production method and use |
MXPA06000975A (en) * | 2003-07-25 | 2006-04-11 | Novartis Ag | Substituted lactams and their use as anti-cancer agents. |
-
2003
- 2003-10-24 DE DE10349669A patent/DE10349669B3/en not_active Expired - Fee Related
-
2004
- 2004-10-08 JP JP2006535987A patent/JP4769190B2/en not_active Expired - Fee Related
- 2004-10-08 MX MXPA06004084A patent/MXPA06004084A/en active IP Right Grant
- 2004-10-08 RS YUP-2006/0263A patent/RS20060263A/en unknown
- 2004-10-08 WO PCT/EP2004/011244 patent/WO2005044803A1/en active Application Filing
- 2004-10-08 CN CNB2004800306469A patent/CN100398520C/en not_active Expired - Fee Related
- 2004-10-08 EP EP04765884A patent/EP1680405B1/en active Active
- 2004-10-08 CN CNA2008100958532A patent/CN101294173A/en active Pending
- 2004-10-08 SI SI200431054T patent/SI1680405T1/en unknown
- 2004-10-08 BR BRPI0415529-7A patent/BRPI0415529A/en not_active IP Right Cessation
- 2004-10-08 AT AT07007021T patent/ATE477244T1/en not_active IP Right Cessation
- 2004-10-08 ES ES04765884T patent/ES2320894T3/en active Active
- 2004-10-08 DE DE502004011536T patent/DE502004011536D1/en active Active
- 2004-10-08 AU AU2004287561A patent/AU2004287561B2/en not_active Expired - Fee Related
- 2004-10-08 PL PL04765884T patent/PL1680405T3/en unknown
- 2004-10-08 DE DE502004008837T patent/DE502004008837D1/en active Active
- 2004-10-08 NZ NZ546744A patent/NZ546744A/en unknown
- 2004-10-08 EP EP07007021A patent/EP1873146B1/en active Active
- 2004-10-08 AT AT04765884T patent/ATE420074T1/en active
- 2004-10-08 PT PT04765884T patent/PT1680405E/en unknown
- 2004-10-08 DK DK04765884T patent/DK1680405T3/en active
- 2004-10-08 RU RU2006117769/04A patent/RU2357956C2/en not_active IP Right Cessation
- 2004-10-08 ME MEP-331/08A patent/MEP33108A/en unknown
- 2004-10-08 CA CA002543003A patent/CA2543003A1/en not_active Abandoned
- 2004-10-08 KR KR1020067007889A patent/KR20060120044A/en not_active Application Discontinuation
- 2004-10-21 AR ARP040103818A patent/AR046553A1/en not_active Application Discontinuation
- 2004-10-22 UY UY28574A patent/UY28574A1/en unknown
-
2006
- 2006-03-16 ZA ZA200602231A patent/ZA200602231B/en unknown
- 2006-03-23 IL IL174524A patent/IL174524A/en not_active IP Right Cessation
- 2006-04-21 MA MA28955A patent/MA28213A1/en unknown
- 2006-05-12 NO NO20062149A patent/NO20062149L/en not_active Application Discontinuation
-
2007
- 2007-02-15 HK HK07101845A patent/HK1098131A1/en not_active IP Right Cessation
-
2009
- 2009-03-19 CL CL2009000674A patent/CL2009000674A1/en unknown
- 2009-03-23 CY CY20091100336T patent/CY1110458T1/en unknown
- 2009-03-31 HR HR20090187T patent/HRP20090187T1/en unknown
Non-Patent Citations (1)
Title |
---|
GROWEISS A. ET AL., "Cytotoxic Metabolites from an Australian Collection of the Sponge Jaspis Species", J. Nat. Prod. 1999, 62, 1691-1693. * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7534591B2 (en) | Bengamide derivatives, process for preparing them, and their use | |
IL174524A (en) | Bengamide derivatives and pharmaceutical compositions comprising them | |
IL202990A (en) | Macrolactone derivatives | |
EP2379074B1 (en) | Macrolactone derivatives, method for the production thereof and use thereof for the treatment of cancer | |
AU2002227966B2 (en) | Coniosetin and derivatives thereof, method for producing the same and use thereof | |
JP5619001B2 (en) | Streptspirol derivative | |
KR100862546B1 (en) | Caloporoside derivatives, methods for the production thereof and medicaments comprising the same | |
AU2002352606B2 (en) | Eurotinone and derivatives thereof, method for the production and use of the same | |
US7160917B2 (en) | Spirobenzofuran lactams and their derivatives, processes for their preparation and use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK25 | Application lapsed reg. 22.2i(2) - failure to pay acceptance fee |